Fingerprint
Dive into the research topics of 'Phase I study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically